EUVIMEDEUVIMED entdecken
Übersichtsarbeit

CKLF1 in cardiovascular and cerebrovascular diseases

Chen Chen, Qidi Ai, Haiyan Tian, Yuhui Wei

International Immunopharmacology · 2024

DOI: 10.1016/j.intimp.2024.112718 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Chen Chen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The First Hospital of Lanzhou University, Lanzhou 730000, China. Electronic address: ery_chenc@lzu.edu.cn. Hauptthemen laut MEDLINE: MARVEL Domain-Containing Proteins, Cardiovascular Diseases, Cerebrovascular Disorders. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 104 Literaturangaben. Gefördert von: Lanzhou City Science and Technology Bureau, National Natural Science Foundation of China, Chinese Pharmaceutical Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chemokine like factor 1 (CKLF1) is a novel atypical chemokine, playing a crucial role in cardiovascular and cerebrovascular diseases (CCVDs) demonstrated by a growing body of works. In cardiovascular diseases including atherosclerosis and myocardial infarction, meanwhile in cerebrovascular diseases such as ischemic stroke and hemorrhagic stroke, the expression levels of CKLF1 change markedly, which triggers downstream signaling pathways by binding with its functional receptors, and then exerts multiple effects to participate in the occurrence and development of these CCVDs. The functional roles of CKLF1 are dynamic and CKLF1 may act as a double-edged sword. The CCVDs-promoting role is related to recruiting inflammatory cells, enhancing the proliferation of vascular smooth muscle cells and endothelial cells, while the CCVDs-suppressing role may correlate with migration of nerve cells and promotion of hematopoietic stem cell proliferation which contributes to disease recovery. Based on this, the paper intends to review expression shifts, potential roles, and molecular mechanisms of CKLF1 in CCVDs, and the current status of CKLF1 targeted therapeutic strategies is also included. We hope this review may provide a valuable reference for using CKLF1 as a diagnostic and prognostic biomarker for CCVDs or developing novel treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MARVEL Domain-Containing ProteinsCardiovascular DiseasesCerebrovascular DisordersHumansAnimalsChemokinesSignal TransductionBiomarkers

Stichwörter der Autor:innen

CCR4CKLF1Cardiovascular diseasesCerebrovascular diseasesInflammation

Substanzen

MARVEL Domain-Containing ProteinsCKLF protein, humanChemokinesBiomarkers

Autor:innen und Institutionen

  • Department of Pharmacy, The First Hospital of Lanzhou University, Lanzhou 730000, China. Electronic address: ery_chenc@lzu.edu.cn.
  • Hunan University of Traditional Chinese Medicine, Changsha 410208, China.
  • Department of Pharmacy, The First Hospital of Lanzhou University, Lanzhou 730000, China.

Förderung

  • Lanzhou City Science and Technology Bureau
  • National Natural Science Foundation of China
  • Chinese Pharmaceutical Association
  • Gansu Province Science and Technology Department
  • Lanzhou University First Affiliated Hospital

Zitieren

APA

Chen, C., Ai, Q., Tian, H., & Wei, Y. (2024). CKLF1 in cardiovascular and cerebrovascular diseases. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112718

Vancouver

Chen C, Ai Q, Tian H, Wei Y. CKLF1 in cardiovascular and cerebrovascular diseases. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112718

BibTeX
@article{Chen2024,
  author = {Chen, Chen and Ai, Qidi and Tian, Haiyan and Wei, Yuhui},
  title = {CKLF1 in cardiovascular and cerebrovascular diseases},
  journal = {International Immunopharmacology},
  year = {2024},
  doi = {10.1016/j.intimp.2024.112718}
}
Kostenlos starten →